Americ

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

WNVis a positive single-stranded RNA flavivirus of about 11 kb. It primarily infe...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused, biopharmaceutical company,today announced that the two-year, follow-up results from theSTRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-ElutingStent Versus Abciximab and Bare Metal Stent In Acute MyocardialInfarct...

Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jul 3, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced thatfurther clinical results from the Company's studies of NX-1207 forbenign prostatic hyperplasia (BPH) will be presented at the NewEngland Section of the American Urological Association Meeting inBoston in September. The paper is authored by leading clinicalresearch inves...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

- Canadian Biotechnology Company updates progress and upcomingmilestones on its insulin program - CALGARY, June 26, 2007 /PRNewswire-FirstCall/ - SemBioSysGenetics Inc. , a biotechnology company developing a portfolio oftherapeutic proteins for metabolic and cardiovascular disease,today announced positive preclinical data supporting thedevelopment of plant-derived recombinant human insuli...

Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting

Presentation Details Statistically Significant Clinical Results forSB-509 in Development for Treatment of Diabetic Neuropathy CHICAGO, June 22, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of encouragingPhase 1 clinical data from its ZFP Therapeutic(TM) program at the67th Scientific Sessions of the American Diabetes Association(ADA). As disclose...

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that data from a preclinicalstudy of trodusquemine (MSI-1436) for the treatment of obesity werepresented during the American Diabetes Association (ADA) 67thScientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz,Genaera research scientist and lead author of Abstract #1801-P,present...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., announced today the publication of clinicaldata highlighting the ability of Glufast(R) (mitiglinide calciumhydrate) monotherapy, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublished in the Abstract Book for the American DiabetesAssociation 67th Annual Scien...

VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc.(NASDAQ: VVUS), a pharmaceutical company dedicated to thedevelopment and commercialization of novel therapeutic products,announced that Abstract #2209-PO, Evaluation of Glycemic Parametersin Obese Diabetic Patients Treated with Phentermine and Topiramate:Outcomes in a Private Practice Setting has been published in theAmerican...

President Bush Ignores America's Plea for Support of Stem Cell Research

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing statement may be attributed to Sean Tipton, president,Coalition for the Advancement of Medical Research (CAMR): "In the face of spiraling health care costs, President Bush onceagain used the stroke of his veto pen deliberately to hamper theprogress of scientific and medical research, as well as endangerthe future hea...

Dean: President Bush Has Turned His Back on the American People

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- DemocraticNational Committee Chairman Howard Dean issued the followingstatement today after President Bush once again put politics aheadof science by vetoing the Stem Cell Research Enhancement Act of2007. The legislation, providing federal funding for life-savingembryonic stem cell research, has the overwhelming support of theAm...

Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of Million of Families Across America

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- SpeakerNancy Pelosi issued the following statement today in response toPresident Bush's veto of the stem cell bill: "Once again, the President has ignored the will of the Americanpeople, of leading medical researchers, and of a bipartisanmajority of the Congress. His cruel veto says 'no' to the hopes ofmillion of families across...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- KeryxBiopharmaceuticals, Inc. today announced that abstracts related toSulonex(TM) (sulodexide oral gelcap) have been selected forpublication or presentation during the poster sessions scheduled totake place at the upcoming American Diabetes Association (ADA) 67thAnnual Scientific Sessions and exposition at the McCormick PlaceLakeside Cen...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced that the Company will present dataabout its lead obesity product candidate Contrave(TM) and itseffect on markers of cardiovascular disease (visceral fat, serumcholestero...

Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting

Company-Sponsored Investor Briefing and Webcast to FollowPresentation DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- BiodelInc. today announced plans to present clinical results of itsleading product candidate, VIAject(TM), at the 67th Annual AmericanDiabetes Association (ADA) Scientific Sessions, to be held inChicago, June 22 through June 26. Biodel's oral presentation at...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

SemBioSys to present new data at American Diabetes Association annual meeting

TSX symbol: SBS CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSysGenetics Inc. , a biotechnology company developing a portfolio oftherapeutic proteins for metabolic and cardiovascular disease,today announced that it will be presenting a scientific poster andabstract at the 67th Scientific Sessions of the American DiabetesAssociation (ADA) in Chicago. The Company's poster will disc...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of the Phase 2proof-of-concept data from the Anthem (Anticoagulation with rNAPc2To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June26th issue of the Journal of of Cardiology (JACC), demonstratingthat higher-dose (greater than or equal to 7.5 mcg/kg) recombinantnematode a...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that it will present a posteron trodusquemine (MSI-1436), its novel anti-obesity compound,during the American Diabetes Association (ADA) 67th ScientificSessions, June 22 to 25 in Chicago. The abstract, # 1801-P, is titled, "Trodusquemine is a MultiplePathway Inhibitor that Causes Diffe...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at American Headache Society Meeting

MONTGOMERY, Ala.--(BUSINESS WIRE)--Jun 8, 2007 - ProEthicPharmaceuticals, Inc., a privately funded specialty pharmaceuticalcompany that acquires, develops, licenses, and markets nicheprescription products, today presented detailed Phase III studydata for PRO-513, the Company's product candidate for the treatmentof migraine headaches. The results were presented in two posterpresentations at...

MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the American Headache Society Meeting

MOUNTAIN VIEW, Calif., June 05, 2007 /PRNewswire/ -- MAPPharmaceuticals, Inc. today announced that it will present Phase 2data from its MAP0004 migraine therapy clinical program at the 49thAnnual American Headache Society Meeting at the Hyatt RegencyChicago in Chicago, Illinois. The poster presentation, which wasaccepted as a late-breaker, is entitled Rapid and SustainedClinical Efficacy...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

2007 American Society of Clinical Oncology (ASCO) AnnualMeeting --Dacogen(R) Activity in Older Patients with AML and inRefractory --Differentiation of the molecular interaction of Aloxi(R)with --Results of a Survival Analysis of Glioblastoma PatientsT...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - MGI Pharma, Inc.(Nasdaq:MOGN), a biopharmaceutical company focused in oncology andacute care, today provided highlights of data presentations madeduring the 2007 American Society of Clinical Oncology (ASCO) AnnualMeeting. Dacogen (decitabine) for Injection was the subject of fiveposters including the presentation of efficacy data in olderpatients with...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model ofnormal human skin found that Menadione was the only agent capableof abrogating the cytotoxic effect of erlotinib * Phase I singleagent Marqibo(r) showed OPTISOME(tm) agent was generally welltolerated in metastatic melanoma patients with an adverse eventprofile similar to conventional vincristine SOUTH SAN FRANCISCO, Calif...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- BostonScientific Corporation today welcomed the publication of an articlein the Journal of of Cardiology (JACC) reviewing the TAXUS ATLASclinical trial, which evaluates the Company's second-generationTAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. Thearticle in the April 24 edition of JACC concluded that the shorterprocedure...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

Data on six products from Pharmion's pipeline provide support forepigenetic and combination therapies, including promising Phase IIIdata on use of Thalidomide to treat multiple myeloma BOULDER, Colo., May 31, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation reported today that data from 18 abstracts of studiesinvestigating the company's marketed and pipeline products will bepresented or...

CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine companyfocused on the development and commercialization ofmultifunctional, tumor-targeted therapies today presented a posterabstract at the 43rd American Society of Clinical Oncology (ASCO)Annual meeting. The poster, entitled "Preliminary Results of aPhase 1 Clinical Trial of CYT-6901," announced the preliminary dataof a National Ca...

AMT Presents Positive Results of Phase I/II Study with Lead Product at Annual Meeting of American Society of Gene Therapy

Efficacy and Safety of Gene Therapy in Lipoprotein LipaseDeficiency Established Amsterdam, The Netherlands - May 31, 2007 - Amsterdam MolecularTherapeutics (AMT), a leader in the field of human gene therapy,reported positive Phase I/II clinical trial results with its leadproduct AMT-010 (now referred to as AMT-011) in CompleteLipoprotein Lipase (LPL) deficient patients at the 10th...

Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting

PALO ALTO, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- AlexzaPharmaceuticals, Inc. announced today that it will present at the49th Annual American Headache Society Meeting the results of aPhase IIb clinical trial of Staccato(R) prochlorperazine (AZ-001)for the acute treatment of migraine headache. The posterpresentation, "Efficacy and tolerability profile of AZ-001(Staccato prochlorpe...

Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - RexahnPharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical companydedicated to the discovery, development, and commercialization ofinnovative treatments for cancer, central nervous system disorders,sexual dysfunction and other unmet medical needs, today announcedthat Dr. John Marshall, Principal Investigator of Phase I clinicaltrial of the...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec(R)-resistant ortreatment-intolerant chronic myelogenous leukemia, will bepresented at the 43rd American Society of Clinical Oncology AnnualMeeting. The meeting takes pl...

Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds

STANFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A new analysishas found that many alcohol treatment studies are designed in waysthat inadvertently omit women and African-Americans fromparticipation. The Stanford University School of Medicineresearcher who led the effort said the findings should remind allscientists that strict study eligibility criteria can haveunintended, negative conseq...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 25, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced that several abstracts featuring itsoncology products, Genasense(R) (oblimersen sodium) Injection, andGanite(R) (gallium nitrate injection), will be presented at the43rd annual meeting of the American Society of Clinical Oncology(ASCO) in Chicago, June 1-5, 2007. The abstracts include thefollowing:...